Research Article
BibTex RIS Cite

Özofagus Skuamoz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 ve Cox-2 Ekspresyonunun Önemi

Year 2020, Volume: 7 Issue: 2, 140 - 147, 30.06.2020
https://doi.org/10.34087/cbusbed.626354

Abstract

Amaç:
Özofagus Sku
amöz Hücreli Karsinomu (ÖSHK) dünyada maligniteler içerisinde sekizinci sırada görülmesine rağmen bulunduğumuz coğrafyada beşinci sırada yer almaktadır. Prognozu oldukça kötü olup beş yıllık sağ kalım oranı %16-20’dir. Surveyinin çok düşük olduğu göz önüne alınacak olursa prognozun belirlenmesi ve tedavinin şekillenmesinde kullanılabilecek yeni belirteçlere ihtiyaç vardır. Bu amaçla son yıllarda önem kazanmış olan COX-2 ve D2-40 belirteçlerinin ÖSHK’lardaki yeri araştırılıp sağ kalım ve prognostik parametrelerle ilişkisi belirlenmeye çalışılmıştır.

Gereç ve Yöntem: Çalışmamızda ÖSHK’da COX-2 ve D2-40 antikorlarıyla immünhistokimyasal boyama uygulanarak boyanmanın yaygınlığı, yoğunluğu, histoskorları ile prognostik parametreler ve sağ kalım arasındaki ilişki istatistiksel olarak değerlendirildi.

Bulgular: COX-2 ile invazyon derinliği, lenfovasküler invazyon, lenf nodu metastazı, klinik evre ve sağ kalım; D2-40 ile klinik evre, lenfovasküler invazyon ve lenf nodu metastazı arasında anlamlı ilişki tespit edildi.

Sonuç: Sonuç olarak her iki belirteç de (D2-40 ve COX-2) ÖSHK’da prognozu belirlemede anlamlı bulundu.

Özofagus Skuamöz Hücreli Karsinomu (ÖSHK) dünyada maligniteler içerisinde sekizinci sırada görülmesine rağmen bulunduğumuz coğrafyada beşinci sırada yer almaktadır. Prognozu oldukça kötü olup beş yıllık sağ kalım oranı %16-20’dir. Surveyinin çok düşük olduğu göz önüne alınacak olursa prognozun belirlenmesi ve tedavinin şekillenmesinde kullanılabilecek yeni belirteçlere ihtiyaç vardır. Bu amaçla son yıllarda önem kazanmış olan COX-2 ve D2-40 belirteçlerinin ÖSHK’lardaki yeri araştırılıp sağ kalım ve prognostik parametrelerle ilişkisi belirlenmeye çalışılmıştır.

Gereç ve Yöntem: Çalışmamızda ÖSHK’da COX-2 ve D2-40 antikorlarıyla immünhistokimyasal boyama uygulanarak boyanmanın yaygınlığı, yoğunluğu, histoskorları ile prognostik parametreler ve sağ kalım arasındaki ilişki istatistiksel olarak değerlendirildi.

Bulgular: COX-2 ile invazyon derinliği, lenfovasküler invazyon, lenf nodu metastazı, klinik evre ve sağ kalım; D2-40 ile klinik evre, lenfovasküler invazyon ve lenf nodu metastazı arasında anlamlı ilişki tespit edildi.

Sonuç: Sonuç olarak her iki belirteç de (D2-40 ve COX-2) ÖSHK’da prognozu belirlemede anlamlı bulunmuştur.



 




Supporting Institution

Atatürk Üniversitesi Tıp Fakültesi

Project Number

2013-243

References

  • 1. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013; 19(34): 5598-5606.
  • 2. Şengül A.T. Özofagus kanserinin epidemiyolojisi. Journal of Experimental and Clinical Medicine 2012; 203-208.
  • 3. Matsui K, Breitender-Geleff S, Soleiman A, Kowalski H, Kerjaschki D. Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. Nephrol Dial Transplant 1999; 1: 9–11.
  • 4. Tong L, Yuan S, Feng F, Zhang H. Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study. Diseases of the Esophagus 2012; 25: 72–80.
  • 5. Ma W, Wang K, Yang S, Wang J, Tan B, Bai B et al. Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7(5): 2361-71.
  • 6. Bai B, Ma W, Wang K, Ha S, Wang JB, Tan B et al. Detection of D2-40 monoclonal antibody-labeled lymphatic vessel invasion in esophageal squamous cell carcinoma and its clinicopathologic significance. Cancer Biol Med. 2013 ;10(2):81-5.
  • 7. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker D.G et al. İncidence of cancer among patients with rheumatoid arthiritis. J. Natl.Cancer Inst. 1993; 85 (4): 307-311.
  • 8. IARC Handbooks on Cancer Prevention, vol. 1: Non-steroidal antiinflamatory drugs. IARC Scientific Publ. Lyon, France, 1997.9. Zhi H, Wang L, Zhang J, Zhou C, Ding F, Luo A et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 2006; 27:1214–21.
  • 9. Zhi H, Wang L, Zhang J, Zhou C, Ding F, Luo A et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 2006; 27:1214–21.
  • 10. Akutsu Y, Hanari N, Yusup G, Komatsu-Akimoto A, Ikeda N, Mori M et al. COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2011; 18:2946–2951.
  • 11. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18:7908-16.
  • 12. Wang F, Duan H, Cai M, Fu J, Ma G, Yang H. Prognostic Significance of the pN Classification Supplemented by Vascular Invasion for Esophageal Squamous Cell Carcinoma. Thorac Cancer. 2015 ; 6(6): 765–771.
  • 13. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.Lancet Oncol. 2011 Jul;12(7):681-92.
  • 14. Oesophageal Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012 (internette web sayfası ) Erişim: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
  • 15. Boran M, Göl H. Özofagus Kanserinde Epidemiyoloji. Turkiye Klinikleri J Surg Med Sci 2007; 3(29):1-4.
  • 16. Kutlay H, Cangır AK, Ökten İ. Özofagus kanserlerinde epidemiyoloji ve risk faktörleri. Türkiye Klinikleri Cerrahi Dergisi 2000; 5:1-3.
  • 17. Liu R, Xu KP, Tan GS. Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed. European Journal of Pharmacology 2015; 769:127-33.
  • 18. Altorki N. COX-2: a target for prevention and treatment of esophageal cancer. J Surg Res 2004;117:114–20.
  • 19. Huang JX, Xiao W, Chen WC, Lin M, Song Z, Chen P et al. Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma. World J Gastroenterol 2010; 16(47): 5975-5981.
  • 20. Takatori H, Natsugoe S, Okumura H, Matsuma M, Uchikado Y, Setoyama T et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2008; 34(4):397-402.
  • 21. Nozoe T, Ezaki T, Kabashima A, Baba H, Maehara Y.. Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. The American Journal of Surgery 2005 189: 110–115.
  • 22. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM et al. Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors. Cancer Res. 2000; 60(5):1306-11.
  • 23. Taketo MM. Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part II). J Natl Cancer Inst 1998; 90:1609–20.
  • 24. Xi H, Baldus SE, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res. 2005; 11(23):8341-7.
  • 25. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002; 190(3):279-86.
  • 26. Cyril Sobolewski, Claudia Cerella, Mario Dicato, Ghibelli L, Diederich M. The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies. Hindawi Publishing Corporation International Journal of Cell Biology Volume 2010, Article ID 215158, 21 pages.
  • 27. Schacht V, Dadras SS, Johnson LA. Up-Regulation of the Lymphatic Marker Podoplanin, a Mucin-Type Transmembrane Glycoprotein, in Human Squamous Cell Carcinomas and Germ Cell Tumors. American Journal of Pathology 2005; 166(3):913-21.
  • 28. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochemical and Biophysical Research Communications 2008; 373: 36–41.
  • 29. Rahadiani N , Ikeda J , Makino T , Tian T , Qiu Y et al. Tumorigenic Role of Podoplanin in Esophageal Squamous-Cell Carcinoma. Ann Surg Oncol 2010; 17:1311–1323.
  • 30. Toll A, Gimeno J, Ferrandiz C. D2-40 immunohistochemical overexpression in cutaneous squamous cell carcinomas: A marker of metastatic risk. J Am Acad Dermatol 2012;67:1310-8.
  • 31. Chen B, Fang WK, Wu ZY, Xu XE, Wu JY, Fu JH et al. The prognostic implications of microvascular density and lymphatic vessel density in esophageal squamous cell carcinoma: Comparative analysis between the traditional whole sections and the tissue microarray. Acta Histochemica 2014;116(4):646-53.
  • 32. Imamura Y, Watanabe M, Nagai Y, Baba Y, Hirashima K, Karashima R et al. Lymphatic Vessel Invasion Detected by the D2-40 Monoclonal Antibody Is an Independent Prognostic Factor in Node-Negative Esophageal Squamous Cell Carcinoma. Journal of Surgical Oncology 2012;105:277–283.
  • 33. Prasad B, Kashyap B, Babu GS, Kumar GR, Manyam R. Expression of Podoplanin in Different Grades of Oral Squamous Cell Carcinoma. Ann Med Health Sci Res. 2015; 5(4):299-304.
  • 34. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007; 104(3):973-8.
Year 2020, Volume: 7 Issue: 2, 140 - 147, 30.06.2020
https://doi.org/10.34087/cbusbed.626354

Abstract

Project Number

2013-243

References

  • 1. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013; 19(34): 5598-5606.
  • 2. Şengül A.T. Özofagus kanserinin epidemiyolojisi. Journal of Experimental and Clinical Medicine 2012; 203-208.
  • 3. Matsui K, Breitender-Geleff S, Soleiman A, Kowalski H, Kerjaschki D. Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. Nephrol Dial Transplant 1999; 1: 9–11.
  • 4. Tong L, Yuan S, Feng F, Zhang H. Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study. Diseases of the Esophagus 2012; 25: 72–80.
  • 5. Ma W, Wang K, Yang S, Wang J, Tan B, Bai B et al. Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7(5): 2361-71.
  • 6. Bai B, Ma W, Wang K, Ha S, Wang JB, Tan B et al. Detection of D2-40 monoclonal antibody-labeled lymphatic vessel invasion in esophageal squamous cell carcinoma and its clinicopathologic significance. Cancer Biol Med. 2013 ;10(2):81-5.
  • 7. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker D.G et al. İncidence of cancer among patients with rheumatoid arthiritis. J. Natl.Cancer Inst. 1993; 85 (4): 307-311.
  • 8. IARC Handbooks on Cancer Prevention, vol. 1: Non-steroidal antiinflamatory drugs. IARC Scientific Publ. Lyon, France, 1997.9. Zhi H, Wang L, Zhang J, Zhou C, Ding F, Luo A et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 2006; 27:1214–21.
  • 9. Zhi H, Wang L, Zhang J, Zhou C, Ding F, Luo A et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 2006; 27:1214–21.
  • 10. Akutsu Y, Hanari N, Yusup G, Komatsu-Akimoto A, Ikeda N, Mori M et al. COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2011; 18:2946–2951.
  • 11. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18:7908-16.
  • 12. Wang F, Duan H, Cai M, Fu J, Ma G, Yang H. Prognostic Significance of the pN Classification Supplemented by Vascular Invasion for Esophageal Squamous Cell Carcinoma. Thorac Cancer. 2015 ; 6(6): 765–771.
  • 13. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.Lancet Oncol. 2011 Jul;12(7):681-92.
  • 14. Oesophageal Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012 (internette web sayfası ) Erişim: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
  • 15. Boran M, Göl H. Özofagus Kanserinde Epidemiyoloji. Turkiye Klinikleri J Surg Med Sci 2007; 3(29):1-4.
  • 16. Kutlay H, Cangır AK, Ökten İ. Özofagus kanserlerinde epidemiyoloji ve risk faktörleri. Türkiye Klinikleri Cerrahi Dergisi 2000; 5:1-3.
  • 17. Liu R, Xu KP, Tan GS. Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed. European Journal of Pharmacology 2015; 769:127-33.
  • 18. Altorki N. COX-2: a target for prevention and treatment of esophageal cancer. J Surg Res 2004;117:114–20.
  • 19. Huang JX, Xiao W, Chen WC, Lin M, Song Z, Chen P et al. Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma. World J Gastroenterol 2010; 16(47): 5975-5981.
  • 20. Takatori H, Natsugoe S, Okumura H, Matsuma M, Uchikado Y, Setoyama T et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2008; 34(4):397-402.
  • 21. Nozoe T, Ezaki T, Kabashima A, Baba H, Maehara Y.. Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. The American Journal of Surgery 2005 189: 110–115.
  • 22. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM et al. Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors. Cancer Res. 2000; 60(5):1306-11.
  • 23. Taketo MM. Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part II). J Natl Cancer Inst 1998; 90:1609–20.
  • 24. Xi H, Baldus SE, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res. 2005; 11(23):8341-7.
  • 25. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002; 190(3):279-86.
  • 26. Cyril Sobolewski, Claudia Cerella, Mario Dicato, Ghibelli L, Diederich M. The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies. Hindawi Publishing Corporation International Journal of Cell Biology Volume 2010, Article ID 215158, 21 pages.
  • 27. Schacht V, Dadras SS, Johnson LA. Up-Regulation of the Lymphatic Marker Podoplanin, a Mucin-Type Transmembrane Glycoprotein, in Human Squamous Cell Carcinomas and Germ Cell Tumors. American Journal of Pathology 2005; 166(3):913-21.
  • 28. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochemical and Biophysical Research Communications 2008; 373: 36–41.
  • 29. Rahadiani N , Ikeda J , Makino T , Tian T , Qiu Y et al. Tumorigenic Role of Podoplanin in Esophageal Squamous-Cell Carcinoma. Ann Surg Oncol 2010; 17:1311–1323.
  • 30. Toll A, Gimeno J, Ferrandiz C. D2-40 immunohistochemical overexpression in cutaneous squamous cell carcinomas: A marker of metastatic risk. J Am Acad Dermatol 2012;67:1310-8.
  • 31. Chen B, Fang WK, Wu ZY, Xu XE, Wu JY, Fu JH et al. The prognostic implications of microvascular density and lymphatic vessel density in esophageal squamous cell carcinoma: Comparative analysis between the traditional whole sections and the tissue microarray. Acta Histochemica 2014;116(4):646-53.
  • 32. Imamura Y, Watanabe M, Nagai Y, Baba Y, Hirashima K, Karashima R et al. Lymphatic Vessel Invasion Detected by the D2-40 Monoclonal Antibody Is an Independent Prognostic Factor in Node-Negative Esophageal Squamous Cell Carcinoma. Journal of Surgical Oncology 2012;105:277–283.
  • 33. Prasad B, Kashyap B, Babu GS, Kumar GR, Manyam R. Expression of Podoplanin in Different Grades of Oral Squamous Cell Carcinoma. Ann Med Health Sci Res. 2015; 5(4):299-304.
  • 34. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007; 104(3):973-8.
There are 34 citations in total.

Details

Primary Language Turkish
Subjects Pathology
Journal Section Araştırma Makalesi
Authors

Onur Ceylan 0000-0001-7025-0521

Nesrin Gürsan This is me 0000-0003-0030-7347

Ayşenur Baş Zeynel 0000-0003-3966-1431

Rabia Demirtaş This is me 0000-0001-8743-1847

Sevilay Özmen 0000-0002-1973-6101

Remzi Arslan This is me 0000-0002-3198-4706

Project Number 2013-243
Publication Date June 30, 2020
Published in Issue Year 2020 Volume: 7 Issue: 2

Cite

APA Ceylan, O., Gürsan, N., Baş Zeynel, A., Demirtaş, R., et al. (2020). Özofagus Skuamoz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 ve Cox-2 Ekspresyonunun Önemi. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 7(2), 140-147. https://doi.org/10.34087/cbusbed.626354
AMA Ceylan O, Gürsan N, Baş Zeynel A, Demirtaş R, Özmen S, Arslan R. Özofagus Skuamoz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 ve Cox-2 Ekspresyonunun Önemi. CBU-SBED: Celal Bayar University-Health Sciences Institute Journal. June 2020;7(2):140-147. doi:10.34087/cbusbed.626354
Chicago Ceylan, Onur, Nesrin Gürsan, Ayşenur Baş Zeynel, Rabia Demirtaş, Sevilay Özmen, and Remzi Arslan. “Özofagus Skuamoz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 Ve Cox-2 Ekspresyonunun Önemi”. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi 7, no. 2 (June 2020): 140-47. https://doi.org/10.34087/cbusbed.626354.
EndNote Ceylan O, Gürsan N, Baş Zeynel A, Demirtaş R, Özmen S, Arslan R (June 1, 2020) Özofagus Skuamoz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 ve Cox-2 Ekspresyonunun Önemi. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi 7 2 140–147.
IEEE O. Ceylan, N. Gürsan, A. Baş Zeynel, R. Demirtaş, S. Özmen, and R. Arslan, “Özofagus Skuamoz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 ve Cox-2 Ekspresyonunun Önemi”, CBU-SBED: Celal Bayar University-Health Sciences Institute Journal, vol. 7, no. 2, pp. 140–147, 2020, doi: 10.34087/cbusbed.626354.
ISNAD Ceylan, Onur et al. “Özofagus Skuamoz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 Ve Cox-2 Ekspresyonunun Önemi”. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi 7/2 (June 2020), 140-147. https://doi.org/10.34087/cbusbed.626354.
JAMA Ceylan O, Gürsan N, Baş Zeynel A, Demirtaş R, Özmen S, Arslan R. Özofagus Skuamoz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 ve Cox-2 Ekspresyonunun Önemi. CBU-SBED: Celal Bayar University-Health Sciences Institute Journal. 2020;7:140–147.
MLA Ceylan, Onur et al. “Özofagus Skuamoz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 Ve Cox-2 Ekspresyonunun Önemi”. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, vol. 7, no. 2, 2020, pp. 140-7, doi:10.34087/cbusbed.626354.
Vancouver Ceylan O, Gürsan N, Baş Zeynel A, Demirtaş R, Özmen S, Arslan R. Özofagus Skuamoz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 ve Cox-2 Ekspresyonunun Önemi. CBU-SBED: Celal Bayar University-Health Sciences Institute Journal. 2020;7(2):140-7.